Furthermore, importantly as with ES-62 [5] and SMA-11a (unpublished), when SMA-12b was administered therapeutically after the onset of arthritis; it protected against further disease development (Fig. 1D). This evidence concerns the gene SMN1 and arthritic joint disease.